Ενημέρωση 12/2019 από τις ADA και EASD για την αντιμετώπιση του διαβήτη τύπου 2
2019 Update to: Management of hyperglycaemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association(ADA) and the European Association for the Study of Diabetes (EASD)
Buse, J.B., Wexler, D.J., Tsapas, A. et al. Diabetologia (2019). https://doi.org/10.1007/s00125-019-05039-w
Abstract: The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomestrials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1(GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events(MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1ctarget; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators ofhigh risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to≤60 ml min−1[1.73 m]−2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.
- από τον server του spikar.gr »»
- από το Diabetologia (EASD) »»
- από το Diabetes Care (ADA) »»
- το αρχείο Management of Hyperglycemia in Type 2 Diabetes, 2018 ADA / EASD link »»